Unlike traditional systemic vaccines, the mRNA vaccine under evaluation is designed to trigger a robust immune response directly at the site of influenza entry, with potential to reduce viral ...
COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year ...
An informational overview examining category context, publicly available product disclosures, and what consumers often consider when researching respiratory support supplement options New York, NY, ...
Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall.
Clinical Claims: According to publicly available disclosures on the company's website, Ivím Health states that its patients lost an average of 46% more weight over 68 weeks compared to another ...
Bicara intends to use the net proceeds of the offering to further invest in and build its medical and commercial infrastructure to support a planned regulatory filing and commercial launch for ...
In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. ET on Thursday, March 12, 2026. The live audio webcast will be accessible on the Company ...
JS207, Junshi Biosciences’ independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both ...
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal ...
Pursuant to section 32 of the Danish Capital Markets Act No. 1493 of November 18, 2025, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is ...
AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter ...
- Advancement reflects continued execution of capital-efficient development strategy leveraging POZ Platform™ - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results